Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | QPCT | Q16769 | 2/20 | 0.44 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 5/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135271 | 0.83 | CSNK2A2 (0.53) | KDM4EALDH1A1HRH3RAB9ASMN1; SMN2 | |
| SCHEMBL6134838 | 0.82 | USP2 (0.48) | KDM4EMAPTALDH1A1HRH3RAB9A | |
| SCHEMBL6134446 | 0.80 | KDM4E (0.51) | KDM4EMAPTALDH1A1TP53HSD17B10 | |
| SCHEMBL6132879 | 0.79 | KDM4E (0.43) | KDM4EMAPTALDH1A1TP53HSD17B10 | |
| SCHEMBL6135056 | 0.79 | RAB9A (0.57) | KDM4EMAPTALDH1A1TP53HSD17B10 | |
| SCHEMBL1143740 | 0.78 | KDM4E (1.00) | KDM4EMAPTALDH1A1TP53HSD17B10 | |
| SCHEMBL6134574 | 0.78 | KDM4E (0.53) | KDM4EMAPTALDH1A1TP53HSD17B10 | |
| SCHEMBL7325400 | 0.78 | KDM4E (0.56) | KDM4EMAPTALDH1A1TP53HSD17B10 | |
| SCHEMBL6132331 | 0.77 | RAB9A (0.44) | KDM4EMAPTALDH1A1TP53HSD17B10 | |
| SCHEMBL27903833 | 0.77 | KDM4E (0.96) | KDM4EMAPTALDH1A1TP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | KDM4E 4301/4885MAPT 1629/4885ALDH1A1 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.